This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: The objective of the study is to compare the safety and immunogenicity of 8 different formulations of rPA102 (50 and 100 ug of rPA protein combined with aluminum adjuvant (0, 82.5, 250, or 750ug/dose).
Showing the most recent 10 out of 515 publications